Regeneron Pharmaceuticals, Inc. and Intellia Therapeutics, Inc. announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron' Products") and research and clinical programs now underway or planned, such as the research programs with Intellia Therapeutics Inc. to develop in vivo CRISPR- based gene editing therapies focused on neurological & muscular diseases discussed in this press release; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as well as Regeneron's collaboration with Intellia discussed in this press release, to be cancelled or terminated; the extent to which the results from the research and development programs conducted by Regeneron and/or's collaborators or licensees (including those conducted as part of the collaboration with Intellia discussed In this press release) may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; the potential of utilizing for therapeutic purposes Regeneron's novel adeno-associated virus (AAV) vectors and delivery systems and Intellia's proprietary Nme2 CRISPR/Cas9 (Nme2Cas9) systems adapted for viral vector delivery as discussed in this press release; The likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products; uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product C and candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary, including those discussed or referenced in this press release) on any of the foregoing or any potential regulatory approval of Regeneron's Products and regeneron's Product Candidates; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, packaging, labeling, distribution, and other steps related to Regeneron's Product Candidates; safety issues resulting from the administration of Regeneron's Products andRegeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products andregon's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regener on's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and RegenerON's Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemics (such as The COVID-19 pandemic pandemics) and research and clinical programs now ongoing or planned, such as the COVID-19emic.